Abbott Laboratories (ABT) fundamentals: P/E, valuation, undervalued?
Abbott Laboratories · Health Care · ref. ETF XLV · price $111.59
In short — Abbott Laboratories trades at 37.0× earnings (P/E), 18.4× forward, with a net margin of 11.6 % and revenue growth of +13 %. Read: Fairly valued (P/E 18 in line with ~13% growth (PEG 1.4)).
Is Abbott Laboratories stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$111.59-15.1% over range
Aug 28, 25low $82.56 · high $136.62Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
100% recommend buying · 17 analysts
Valuation : Fairly valued — P/E 18 in line with ~13% growth (PEG 1.4)
Valuation
37.0
P/E (price/earnings)
18.4
Forward P/E
—
PEG
3.8
Price/book (P/B)
$193.1B
Market cap
3.02
EPS
Profitability & growth
11.6 %
Net margin
+13 %
Revenue growth
-48 %
Earnings growth
$32.7B
Total debt
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Abbott Laboratories's P/E and is the stock undervalued? What's a good P/E?
Abbott Laboratories's P/E is 37.0 (forward 18.4). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Fairly valued".
Is Abbott Laboratories profitable?
Abbott Laboratories has a net margin of 11.6 % (EPS 3.02). The company is profitable.
Is ABT stock expensive?
Our read: "Fairly valued" — P/E 18 in line with ~13% growth (PEG 1.4). Cross-check with growth and sector.
💬 A question about Abbott Laboratories? The JPI assistant answers using our backtest data.